SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Shire Pharmaceuticals Group plc Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD